Shane Kannarr, OD
Optometrist · Pittsburg, KSNPI 1891772489
Payments from drug & device makers
Across 2,651 payments — averaging $1657.40 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Johnson & Johnson Vision Care, Inc.$1.5M
- Alcon Research LLC$922K
- AbbVie$772K
- Oyster Point Pharma, Inc.$229K
- Bausch & Lomb Americas Inc.$206K
- Sight Sciences, Inc.$193K
- plus $552K from 23 others
Across 4 payments — averaging $19,011 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Coopervision Inc.$74K
- Bausch Health US, LLC$3K
What the payments were for
- Consulting fees$111,99521%
- Speaking & faculty fees$335,78063%
- Travel & lodging$54,19710%
- Food & beverage$27,0995%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Johnson & Johnson Vision Care, Inc. | 489 | $1,520,178 |
| Alcon Research LLC | 1,175 | $921,915 |
| AbbVie(2 entities) | 423 | $771,520 |
| Oyster Point Pharma, Inc. | 35 | $228,687 |
| Bausch & Lomb Americas Inc. | 99 | $206,155 |
| Sight Sciences, Inc. | 28 | $192,946 |
| Novartis | 28 | $140,921 |
| Bausch Health US, LLC | 10 | $82,365 |
| Tarsus Pharmaceuticals, Inc. | 144 | $76,309 |
| Sun Pharmaceutical Industries Inc. | 71 | $66,034 |
| Coopervision Inc. | 18 | $63,505 |
| Topcon Healthcare, Inc. | 13 | $55,935 |
| Osmotica Pharmaceutical Corp. | 21 | $32,612 |
| Shire North American Group Inc | 5 | $10,228 |
| Astellas Pharma US Inc | 3 | $8,658 |
| Apellis Pharmaceuticals, Inc. | 8 | $4,188 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $3,334 |
| Alcon | 32 | $3,016 |
| Glaukos Corporation | 2 | $1,804 |
| Kala Pharmaceuticals, Inc. | 17 | $1,044 |
| Johnson & Johnson Surgical Vision, Inc. | 2 | $939 |
| Vertical Pharmaceuticals, LLC | 1 | $800 |
| Bausch & Lomb, A Division Of Bausch Health US, LLC | 17 | $275 |
| Dompe US, Inc. | 4 | $167 |
| Amgen | 1 | $83 |
| Optovue, Inc. | 1 | $81 |
| LKC Technologies, Inc. | 1 | $33 |
| ABB Con-cise Optical Group LLC | 1 | $16 |
| Maculogix, Inc. | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$4,393,762 in reported general payments places this provider in the 95th percentile of 567 optometrist providers in Kansas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| RestasisCyclosporine | 88 | $102,361 |
| XdemvyLotilaner | 32 | $60,716 |
| XiidraLifitegrast | 51 | $46,834 |
| LumiganBimatoprost | 60 | $28,443 |
| MieboPerfluorohexyloctane/Pf | 14 | $10,451 |
| VyzultaLatanoprostene Bunod | 22 | $8,327 |
| Cyclosporine | 12 | $5,096 |
| CombiganBrimonidine Tartrate/Timolol | 17 | $4,869 |
| Prednisolone Acetate | 64 | $3,138 |
| Loteprednol Etabonate | 21 | $2,763 |
| Latanoprost | 171 | $1,188 |
| Ketorolac Tromethamine | 35 | $1,020 |
| Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol | 11 | $893 |
| Tobramycin-DexamethasoneTobramycin/Dexamethasone | 12 | $612 |
| Ofloxacin | 28 | $367 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieRestasis, Lumigan, Combigan | $771,520 | $135,673165 claims |
| Bausch & Lomb Americas Inc.Xiidra, Miebo, Vyzulta | $206,155 | $65,61287 claims |
| Tarsus Pharmaceuticals, Inc.Xdemvy | $76,309 | $60,71632 claims |
| Bausch & Lomb, A Division Of Bausch Health US, LLCLoteprednol Etabonate | $275 | $2,76321 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 567 optometrist providers in Kansas.
Other optometrist in Pittsburg
- Christopher JacquinotPittsburg$4K
- Jeffry GersonOlathe$619K
- Brenda EdwardsShawnee Mission$342K
- Jason PingelMission$244K
- Justin WeigelOlathe$220K
- Chad ThompsonBeloit$96K
- Brandon HunterLeawood$68K
- Jonathan ReddellLeavenworth$56K
- Raymond BrillMission$19K
- Jeremy GardnerWichita$17K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.